Alaunos Therapeutics (TCRT) has released an update.
Alaunos Therapeutics, Inc. has approved a reverse stock split of its common stock at a ratio of 1-for-15, to take effect on January 31, 2024. The stock will trade on The Nasdaq Capital Market with a new CUSIP number post-split. This decision, determined by the Board of Directors with a stockholder-approved range of 1-for-5 to 1-for-15, follows the initial Board approval and subsequent stockholder endorsement at the annual meeting. Equiniti Trust Company will manage the exchange of shares for stockholders.
For further insights into TCRT stock, check out TipRanks’ Stock Analysis page.
